$50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Legislation related to spinal cord injury research and treatment. Legislation related to central nervous system research and therapeutics. Legislation related to spinal cord injury research, therapeutics and approvals."
You can find more data on corporate lobbying on Quiver Quantitative.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
